Roctavian
Payments companies reported to CMS as associated with Roctavian. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Roctavian, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Roctavian
These are the largest totals companies reported as associated with Roctavian. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Guy Young | Bozeman, MT | Pediatric Hematology-Oncology | $44,539.63 |
| Steven Pipe | Ann Arbor, MI | Pediatric Hematology-Oncology | $16,763.52 |
| Amit Soni | Orange, CA | Pediatric Hematology-Oncology | $16,411.48 |
| Jonathan Roberts | Peoria, IL | Pediatrics | $15,926.51 |
| Maissaa Janbain | New Orleans, LA | Hematology & Oncology | $15,647.41 |
| Ronald Rosenfeld | Broomall, PA | Orthopaedic Surgery | $14,400.00 |
| Elaine Majerus | Saint Louis, MO | Hematology (Internal Medicine) | $13,707.42 |
| Jordan Shavit | Ann Arbor, MI | Pediatric Hematology-Oncology | $10,818.43 |
| Jennifer Davila | Bronx, NY | Pediatric Hematology-Oncology | $10,182.57 |
| Vivek Sharma | Louisville, KY | Hematology & Oncology | $9,787.73 |
Prescribed Roctavian?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.